AIM ImmunoTech Investor Relations Material
Latest events
Q3 2024
AIM ImmunoTech
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from AIM ImmunoTech Inc
Access all reports
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., is an immuno-pharmaceutical company dedicated to the research and development of therapeutics for the treatment of multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's leading product candidate is Ampligen, a drug composed of macromolecular ribonucleic acid molecules aimed at treating chronic fatigue syndrome (CFS). Ampligen is also under development for various cancer types, including renal cell carcinoma, malignant melanoma, and others, as well as for conditions like Hepatitis B, HIV, COVID-19, and post-COVID conditions. Another key product is Alferon N Injection, an injectable formulation of natural alpha interferon for treating human papillomavirus (HPV) and genital warts. The company is headquartered in Ocala, Florida, and its shares are listed on the NYSE.
Latest articles
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Anthony Noto: The Multifaceted CEO of SoFi
Anthony Noto built a successful and diverse career across multiple industries before becoming CEO of the fintech company SoFi.
9 Dec 2024
Master of Tickets: Breaking Down Live Nation Entertainment
Since merging in 2010, Ticketmaster and Live Nation have built an expansive ecosystem that dominates global live entertainment.
6 Dec 2024
Ticker symbol
AIM
Country
🇺🇸 United States